Current Cancer Drug Targets - Volume 22, Issue 8, 2022

Immunotherapy can be considered a therapeutic revolution in oncology, with great impact on many tumor types, such as melanoma and non-small cell lung cancer. However, in metastatic colorectal cancer, the benefits in terms of prolonged tumor control and high response rate are limited to the rare subgroup of tumors with high mutation burden - mostly tumors that harbor microsatellite instability (MSI) or a deficient mismat Read More

Background: The treatment options for GEP-NENs include various drugs and are based on grading, morphology, and location of the primary. Objective: The aim of our work is to investigate the clinical impact of new immune checkpoint inhibitors in order to define a new possible strategy of use within GEP-NENs. Methods: A scientific literature search from 2015 to January 2020 was performed using PubMed and Embase: re Read More

BTC is a rare and aggressive cancer disease, bearing an overall dismal prognosis with only finite therapy options. Only combination chemotherapy regimens achieve disease control, which is often only short-lived since the tumor tissue exhibits high resistance to chemotherapy. The emergence of immune checkpoint inhibitors in recent years has significantly improved the survival of cancer patients and thus, has been integrated Read More

Immunotherapy represents one of the biggest breakthroughs of the 21st century and redefined modern cancer treatment. Despite this new approach changing the treatment paradigm in various cancer entities, including lung and head-and-neck cancer, the efficacy of these treatment regimens varies in different patient subgroups, and so far, these treatment regimens have failed to meet the high expectations of gastr Read More

Immunotherapy continues to redefine the solid tumor treatment landscape, with inhibitors of the PD-L1/PD-1 immune checkpoint having the most widespread impact. As the most common cancer diagnosed worldwide, there is significant interest in the development of immunotherapy for the treatment of breast cancer in both the early and metastatic settings. Recently reported results of several clinical trials have identified po Read More

Chordoma is a rare, slow-growing sarcoma that is locally aggressive and typically resistant to conventional chemo- and radiotherapies. Despite its low incidence, chordoma remains a clinical challenge because therapeutic options for chordoma are limited, and little is known about the molecular mechanisms involved in resistance to therapies. Furthermore, there are currently no established predictive or prognostic biomarkers to Read More

Background: Gastric cancer (GC) is the fourth most commonly found cancer and the second- highest cause of cancer-related death worldwide. TROP2 overexpression is closely related to many cancers, including gastrointestinal tumors. DSG2 is an important protein in cell adhesion, and its loss affects cell migration. Aims and Objective: This study aimed to explore the specific mechanism of TROP2 in promoting gastric cance Read More